

Ayuda Proyectos Generales AECC 2024

Adjudicatarios

Dr. David Sancho

Centro Nacional de Investigaciones
Cardiovasculares (CNIC)

Generation of bispecific antibodies targeting T lymphocytes and dendritic cells to increase their interaction in the tumor setting and promote anti-tumor immunity

Dr. Lluís Espinosa

Hospital del Mar Research Institute

Uncovering the mechanisms of fetal conversion in Cancer: Functional consequences and clinical impact.

Dr. Francesc Posas

Instituto de Investigación Biomédica (IRB Barcelona)

Harnessing an alternative RB1 activation mechanism for a potential breast cancer therapy

Dra. Maite Huarte

Cancer Center Clínica Universidad de Navarra (CIMA-CCUN)

Leveraging RNA biology to identify vulnerabilities in ovarian cancer

Dra. Patricia Aspichueta

Universidad del País Vasco (UPV/EHU)

Novel mechanisms for prevention and diagnosis of colorectal cancer liver metastasis: reprogramming cholesterol metabolism in hepatocytes

Dr. Jesús María Bañales

Instituto de Investigación Sanitaria Biogipuzkoa (IIS Biogipuzkoa)

Identifying the Danger: Multi-omics in the Path for Precision Medicine in Biliary Tract Cancer (CHOLANGIOMIC)

Dr. José Tubio

Centro Singular de Investigación en Medicina Molecular y Enfermedades Crónicas (CiMUS)

Exploring the impact of retrotransposon-Chimeric neoantigens on immune response for cancer therapy

Dra. Alena Gros

Vall d'Hebron Instituto de Oncología (VHIO)

Precision Immunotherapy: Harnessing TCR T Cell Therapies to Target Recurrent Cancer Mutations in PIK3CA and KRAS (PI-TCR ACT)

Suplementes

Dr. Pablo Huertas

Universidad de Sevilla (US)

Improving radiation-induced DNA damage effect on cancer cells using chronotherapy

Dr. Matthias Drosten

Centro de Investigación del Cáncer (CSIC - Universidad de Salamanca)

The PEA3 protein family as a therapeutic target for KRAS-mutant lung cancer

Dr. Juan Montero

Universitat de Barcelona (UB)

Novel therapies to overcome therapy resistance in pediatric acute lymphoblastic leukemia

Dra. Cristina Rodríguez

Instituto de Investigaciones Biomédicas Sols-Morreale IIBM (CSIC-UAM)

Hypoxia Inducible Factor 2 alpha inhibitors: molecular determinants of sensitivity and biomarkers of response in renal cancer and other tumors